OSE Immunotherapeutics SA (FRA:6OP)

Market Cap	68.11M -52.4%
Revenue (ttm)	1.78M -95.8%
Net Income	-32.52M
EPS	-1.48
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	25
Open	2.856
Previous Close	3.120
Day's Range	2.856 - 2.950
52-Week Range	2.856 - 7.165
Beta	n/a
RSI	20.79
Earnings Date	Apr 29, 2026

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 64
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6OP